Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

Journal:

The Lancet Oncology

Published:

2025-05-02

DOI:

10.1016/s1470-2045(25)00097-x

Affiliations:

25

Authors:

49

Go to article

Institutions	Authors	Share
University of Tübingen (Uni Tübingen), Germany	5.041667	0.16
Hannover Medical School (MHH), Germany	4.541667	0.14
West German Study Group GmbH, Germany	3.041667	0.10
Charité - University Medicine Berlin, Germany	1.875000	0.06
Evangelical Hospital Mönchengladbach BETHESDA, Germany	1.208333	0.04
Jerusalem Hospital Hamburg, Germany	1.041667	0.03
Diakovere Hospital, Germany	1.041667	0.03
Institut für Pathologie Viersen, Germany	1.041667	0.03
Gynonco Düsseldorf, Germany	1.041667	0.03
Queen Mary University of London (QMUL), United Kingdom (UK)	1.041667	0.03
Brandenburg Medical School - Theodor Fontane (MHB), Germany	1.041667	0.03
University Hospital Tübingen (UKT), Uni Tübingen, Germany	1.041667	0.03
Niels-Stensen-Kliniken, Germany	1.041667	0.03
Red Cross Hospital Munich gGmbH, Germany	1.041667	0.03
GFO Kliniken Troisdorf, Germany	1.041667	0.03
Onkodok, Germany	1.041667	0.03
Comprehensive Cancer Center München, Germany	1.041667	0.03
Witten/Herdecke University (UW/H), Germany	0.916667	0.03
Kliniken Essen-Mitte, Germany	0.875000	0.03
Klinikum Dortmund gGmbH, Germany	0.541667	0.02
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany	0.541667	0.02
University Medical Center Freiburg, Germany	0.541667	0.02
University Hospital of Cologne, Germany	0.375000	0.01

Interested in Oncology and Carcinogenesis?